🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Medico Remedies Limited MEDICO NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://medicoremedies.com
Company Profile ↓
₹39.10
-4.87% 1Y
Mkt Cap₹324.47 Cr
P/E32.05
P/B4.28
52W High₹54.24
52W Low₹32.76
Book Value₹9.10
EPS (TTM)₹1.22

Company Overview

Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.4%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 26.2%.

Consistent Profit Growth

Net profit has compounded at 21.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 14.2% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 32.0, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.25.

Recent Developments

  • Mar 2026 Revenue of ₹206.38 Cr (+36.7% YoY); net profit ₹13.12 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +36.7%, earnings +29.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 14.2%, profit CAGR 21.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:14.22%
1 Year:36.73%

Compounded Profit Growth

5 Years:21.89%
1 Year:29.94%

Stock Price Performance

1 Year:-4.87%
6 Months:-19.98%
3 Months:-0.53%
1 Month:-7.94%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 30% of range
₹32.76 ₹54.24
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)37.72 · Neutral
Price Performance
1M-7.94%
3M-0.53%
6M-19.98%
1Y-4.87%
Valuation vs Sector

P/E of 32.05 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 26.2%.
  • Compounding revenue at 14.2% over 5 years.
  • Profit CAGR of 21.9% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 27.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
32.05
Industry PE
39.97
Forward P/E est.
24.67
PEG Ratio
-
Book Value
₹9.10
Price to Book
4.28
P/S
1.58
EV/EBITDA
19.88
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
14.22%
Profit 5Y
21.89%
Revenue (YoY)
36.73%
Earnings (YoY)
29.94%

Profitability & Returns

ROCE
26.22%
ROE
17.38%
ROA
8.55%
Profit Margin
6.35%
Op Margin
6.75%
Gross Margin
26.67%
EPS (Latest Qtr)
₹0.71
EPS (TTM)
₹1.22

Balance Sheet & Liquidity

Debt/Equity
0.25
Quick Ratio
1.27
Current Ratio
1.66
Debt
₹19.20 Cr
Total Assets
₹153.40 Cr
Current Assets
₹128.92 Cr
Working Capital
₹51.27 Cr

Ownership

Promoter Holding
69.45%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹324.47 Cr
Total Revenue (TTM)
₹206.38 Cr
EBITDA
₹22.96 Cr
Free Cash Flow
₹1.38 Cr
Operating Cash Flow
₹5.87 Cr
Shares Outstanding
₹8.30 Cr
Gross Margin
26.67%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MEDICO Medico Remedies Limited NSEPHARMA 39.10 32.05 ₹324.47 Cr 0.00% 26.22% 17.38% 14.22% 21.89%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -41.30 Cr38.25 Cr52.64 Cr58.68 Cr56.81 Cr
Cost of Revenue -27.36 Cr27.34 Cr40.44 Cr44.11 Cr39.44 Cr
Gross Profit -13.94 Cr10.91 Cr12.19 Cr14.57 Cr17.37 Cr
Operating Expenses -8.04 Cr8.86 Cr10.21 Cr11.03 Cr11.02 Cr
Operating Income -5.90 Cr2.06 Cr1.98 Cr3.54 Cr6.35 Cr
EBITDA -6.96 Cr3.48 Cr4.44 Cr5.01 Cr10.02 Cr
Interest Expense -49.40 L28.11 L23.51 L38.63 L90.38 L
Pretax Income -5.70 Cr2.43 Cr3.47 Cr3.83 Cr8.32 Cr
Tax Provision -1.36 Cr61.58 L90.59 L96.00 L2.46 Cr
Net Income -4.34 Cr1.82 Cr2.57 Cr2.87 Cr5.86 Cr
Diluted EPS -0.520.220.310.350.71

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -138.50 Cr143.31 Cr150.94 Cr206.38 Cr
Cost of Revenue -112.73 Cr118.60 Cr108.33 Cr151.33 Cr
Gross Profit -25.77 Cr24.71 Cr42.61 Cr55.05 Cr
Operating Expenses -18.87 Cr14.68 Cr30.64 Cr41.12 Cr
Operating Income -6.90 Cr10.03 Cr11.97 Cr13.93 Cr
EBITDA -16.12 Cr14.86 Cr17.69 Cr22.96 Cr
Interest Expense -58.04 L64.25 L1.16 Cr1.81 Cr
Pretax Income -10.10 Cr11.33 Cr13.50 Cr18.06 Cr
Tax Provision -2.86 Cr3.04 Cr3.41 Cr4.94 Cr
Net Income -7.24 Cr8.29 Cr10.09 Cr13.12 Cr
Diluted EPS 0.580.871.001.22-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -87.45 Cr96.20 Cr119.80 Cr153.40 Cr
Current Assets -64.54 Cr73.71 Cr96.68 Cr128.92 Cr
Cash & Equivalents -91.14 L18.27 L1.09 Cr1.91 Cr
Inventory -19.70 Cr16.34 Cr26.73 Cr30.02 Cr
Receivables -36.09 Cr49.63 Cr57.18 Cr81.99 Cr
Total Liabilities -43.61 Cr43.82 Cr57.33 Cr77.93 Cr
Current Liabilities -41.77 Cr42.81 Cr56.96 Cr77.64 Cr
Long Term Debt -00028.63 L
Total Debt -9.76 Cr8.05 Cr14.70 Cr19.20 Cr
Total Equity -43.84 Cr52.37 Cr62.47 Cr75.47 Cr
Shares Outstanding -8.30 Cr8.30 Cr8.30 Cr8.30 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -8.17 Cr2.44 Cr4.89 Cr5.87 Cr
Investing Cash Flow --6.60 Cr-2.68 Cr-3.46 Cr-4.51 Cr
Financing Cash Flow --1.82 Cr-49.00 L-52.00 L-55.00 L
Capital Expenditure --6.59 Cr-2.48 Cr-3.19 Cr-4.49 Cr
Free Cash Flow -1.57 Cr-4.04 L1.70 Cr1.38 Cr
Net Change in Cash --25.36 L-72.87 L91.22 L81.19 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -18.6%17.2%28.2%26.7%
Operating Margin % -5.0%7.0%7.9%6.8%
Net Margin % -5.2%5.8%6.7%6.4%
ROE % -16.5%15.8%16.2%17.4%
ROCE % -15.1%18.8%19.1%18.4%

Shareholding Pattern

Insiders
69.45%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MEDICO

Google News hu, 09 Jul 2026

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNdU5yalRKdDJKa2dseDYxc3Q2UDV0b1FZV1Nnb1BhU3pWY2phLU4yLTZCb0tteThGbFpIcUh6YnJnck43Zmxydy10ZGI2dVh4bHc0TTdDWWo0dUZjNFJ2VVNQbnBLY2ZaRFhscWw5WURmcWRydkFfbWlIWEQ2SG1jRXZEajJoOERlZGhtbz…

Google News Sat, 11 Jul 2026

Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lows - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQdldjeTE2THdhTUZBNXlaSHdTZ3B3YWczd1R4Qk1XaHljbzkzQUdUem1zbWhVeWN1UHQ0eXhTYTBnNGdHQ2hGM3Jmb1FFa25XMXRjUDR2MEdNemR1UzRTVnBLN0hUYmdLMngzcEkxSmh5eURydUg3UERrNFFwODk4cFp1aHg0cm95Z3AwTT…

Google News Mon, 27 Apr 2026

Simple training can save lives by keeping medical supplies on the shelves, UT San Antonio researcher finds - UT San Antonio Today

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPVmtISEVyN2U3YkZRQXlxUVMtVHFPQW9tZEtHeXZ5dXI5Mk9QR2MwaE9RUTBwRnI1V0xsQmcxZUdwWjZ2QjhEcUJwTV9EX3ZiOWRuNkNieUl0OTE4aDVYRm83OVZuaU9aOWxWc0tUZ1RLOEtEUk5LTnpleEo2dmRiTTJkNlh6TlpRbFkyan…

Google News Mon, 29 Jun 2026

Medical Services Name Tests For Colon Cancer. Natera Stock Hits A High. - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNbW5yZXB0bE5zazA1cU80QmNpZFVWYWRjWGVmZEFiTjdxbW1yME42VFoxUnYwTUdLNGxGd19hT0Qwc3VqdC01RmZjZFU3NHdLaDNoaEttZE9OaVZUX2lvbHdpcjU0bVZZN0t3NDNkQUZWYlpfckQ1cHRobG9WX0p2Umg2Nk5nMzVNRWgyUn…

Google News ue, 02 Jun 2026

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance - PR Newswire

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNS0ZVb2NPS1JLN3IxX21LNFllQ1BKZHlIbFdOYmpDVDNnbldkOHNrWVROZFNKRnZuRUNxWjdxRWtETzlCNTBYNGRhZ1J0REU1ME9WdkxuREJoaEtpLWdsR1lfeDlYMGkwYXZBYmlWWVlFSHVKX3lWZUp6ZGg1dEtuaG5ka01kSGxKaE1HVC…

Google News ue, 05 May 2026

Inspire Medical Systems (INSP) Stock Trades Down, Here Is Why - StockStory

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOUHE3ZEIwMlhTWExQbkxaMk1DTVBidGRwcG9sN3kzaFcwUUpzSkgzdTFMOWFBVTdoaWtpMDZSSWdYcWJJd0JUTUstYU9lRUxuV1Z3M3RFMUIzdDBLNGFMVzNDWXBRb2xuMWVkbEF3ZzJJdkxocWdrajhjVVMxZnR1X3dzWTN1a0VGYW1QZG…

MEDICO — Frequently Asked Questions

What is the current share price of Medico Remedies Limited (MEDICO)?

As of 2026-07-15 09:52 IST, Medico Remedies Limited (MEDICO) trades at ₹39.10 on NSE. Its 52-week range is ₹32.76 to ₹54.24.

What is the market capitalisation of MEDICO?

Medico Remedies Limited (MEDICO) has a market capitalisation of ₹324.47 Cr on NSE.

What is the P/E ratio of MEDICO?

MEDICO trades at a trailing price-to-earnings (P/E) ratio of 32.05. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.28.

What is the return on equity (ROE) of MEDICO?

MEDICO has a return on equity (ROE) of 17.38%. Its return on capital employed (ROCE) is 26.22%.

Is MEDICO a good stock to buy?

This page provides a data-driven analysis of Medico Remedies Limited (MEDICO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space